

Statement from BIOTECCanada on Health Canada Approval of the Pfizer-BioNTech COVID-19 Vaccine

December 9, 2020 [OTTAWA] - BIOTECCanada, the national biotechnology industry association, recognizes and applauds the significant expertise and dedication of the Canadian regulatory system and regulators who have today provided the safety approval for the first COVID-19 vaccine for Canadians.

“With today’s announcement, Canadians should be proud and confident of the uncompromising work conducted by Health Canada and the Public Health Agency which has provided for the timely approval of and access to the Pfizer- BioNTech-Acuitas mRNA vaccine for Canadians,” offered Andrew Casey, President and CEO, BIOTECCanada.

“With more vaccine candidates soon to be brought forward, it is important to recognize the efficient and thorough work of Health Canada and the Public Health Agency officials in providing this approval. It is vital Canadians are aware of the scientific regulatory process followed by Canadian regulators to ensure that critical Canadian safety and efficacy protocols are met. This is important not only for the Pfizer vaccine but also for the other COVID-19 vaccine candidates expected over the period ahead.”

For more information:
Nadine Lunt
Nadine.lunt@biotech.ca